Clinical trial

Pediatric Schizophrenia Efficacy and Safety Study

NCT01911429

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2013-08-01

PhasePHASE3

Study timeline

Study start (unknown)2013-08-01Date precision: month

Registry last updated2017-04-18

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Schizophreniaunresolved

Interventions

Lurasidone 40 mgDRUG

Lurasidone 80 mgDRUG

Placebo 40 or 80 mgDRUG

Sponsors & collaborators

Sumitomo Pharma America, Inc.lead sponsor

Mapped research locations

Saint PetersburgRussia2 KharkivUkraine2 MonterreyMexico2 New YorkNew York, United States1 DallasTexas, United States1 BaltimoreMaryland, United States1 AtlantaGeorgia, United States1 SeoulSouth Korea1 BarcelonaSpain1 ClevelandOhio, United States1 CincinnatiOhio, United States1 Washington D.C.District of Columbia, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01911429 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.